For in vitro diagnostic use. The RIDASCREEN® VDZ Monitoring is an enzyme linked immunosorbent assay intended for the quantitative determination of vedolizumab (VDZ, Entyvio®, anti- integrin α4β7) in human serum and plasma.
Vedolizumab (VDZ, Entyvio®) is approved for the treatment of patients with moderate to severe Crohn’s disease and ulcerative colitis in whom conventional therapy or anti-TNFα therapies were ineffective or not tolerated. It is a gut-specific, humanized monoclonal antibody targeting the α4β7-integrin protein, which is involved in the migration of lymphocytes to the gut. Similar as to anti-TNFα drugs, measurement of vedolizumab drug concentrations supports a personalized dosing strategy in patients treated with vedolizumab.
The RIDASCREEN® VDZ Monitoring and our other TDM assays are vital to personalize treatment of patients with Crohn’s disease and ulcerative colitis and better achieve therapeutic targets.
- CE-marked versions of the ELISA tests of KU Leuven
- Highly specific antibodies
- Ready to use reagents
- Validated for use on automated ELISA systems, e.g. the Dynex DSX®
|Test format||Microtiter plate with 96 wells (12 strips with 8 removable wells each)|
|Incubation time||1 h 40 min|